Dr. Guy Katz, MD

Dr. Katz practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Katz's NPI, 1285168187, was assigned on April 18, 2017. Dr. Katz graduated from Icahn School of Medicine at Mount Sinai in 2017. Dr. Katz holds Massachusetts license 291283.

Dr. Katz's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Katz's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Katz is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Katz to 3 more hospitals, 1 community health center and 1 medical group, each named with a free account. Dr. Katz's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Katz practices, 6 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Katz's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Katz is licensed in Massachusetts.

CMS data shows 235 Medicare services from Dr. Katz across 5 procedure codes in 2024, for 165 Medicare patients. Medicare paid $21,031 for them.

CMS counts 165 Medicare patients who saw Dr. Katz in 2024. The largest group is 75 to 84, with 64 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Katz's median patient age at 73, with 56% women.

In 2024, Dr. Katz wrote 709 Medicare Part D claims for 119 patients. 53% of them were for generic drugs. CMS names the drug for 574 of them, across 18 drugs with 11 or more claims each, at $1,657,267 in total drug cost. In 2023, CMS named 288 claims across 14 drugs.

Dr. Katz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Katz as offering telehealth.

Dmand AI links 18 papers to Dr. Katz, published from 2020 to 2025. 2024 was the busiest year, with 7. The most frequent topics are Immunoglobulin G4-Related Disease, Immunoglobulin G and Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Dr. Katz has published most often in Semin Arthritis Rheum. Dr. Katz's most frequent co-authors are John H. Stone, MD, Zachary S. Wallace, MD and Cory Adam Perugino, DO.

CMS Open Payments shows 31 general payments to Dr. Katz from 2 drug and device companies from 2019 to 2025. Consulting fees make up the largest share, 84% of the total. Amgen Inc. paid the most, $27,614.

Dr. Katz graduated from Icahn School of Medicine at Mount Sinai in 2017.